Polar Capital Holdings’s Vaxcyte PCVX Stock Holding History

Polar Capital Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.9M	Sell	1,185,943 -239,845	-17%	-$13M	0.16%	104
2026 Q1	$82.9M	Sell	1,425,788 -246,995	-15%	-$13.4M	0.29%	72
2025 Q4	$77.2M	Buy	1,672,783 +1,257,253	+303%	+$56.2M	0.3%	78
2025 Q3	$15M	Sell	415,530 -410,265	-50%	-$13.6M	0.07%	174
2025 Q2	$26.8M	Sell	825,795 -256,678	-24%	-$8.41M	0.14%	123
2025 Q1	$40.9M	Buy	1,082,473 +108,828	+11%	+$8.7M	0.25%	109
2024 Q4	$79.7M	Sell	973,645 -22,134	-2%	-$2.2M	0.45%	60
2024 Q3	$114M	Buy	+995,779	New	+$89.7M	0.54%	44

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Polar Capital Holdings's PCVX Position: Q2 2026 in Review

Polar Capital Holdings reduced its Vaxcyte (PCVX) stake by 17% in Q2 2026, selling an estimated $13M and leaving 1,185,943 shares worth $68.9M. The position accounts for 0.16% of the portfolio, ranked #104.

Polar Capital Holdings first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $114M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Polar Capital Holdings held 1,185,943 shares of Vaxcyte worth $68.9M as of Q2 2026.
Polar Capital Holdings sold 239,845 Vaxcyte shares in Q2 2026, an estimated $13M.
Vaxcyte made up 0.16% of Polar Capital Holdings's portfolio in Q2 2026, its #104 holding.
Polar Capital Holdings first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
Polar Capital Holdings's Vaxcyte position peaked at $114M in Q3 2024.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.